New CNN poll shows virtual tie between Harris and Trump
Rudy Giuliani owes $300,000 to firm that worked on his bankruptcy case, judge says
Georgia court could reject counting presidential votes for Cornel West and Claudia De la Cruz
US to send $375 million in military aid to Ukraine, including medium-range cluster bombs
Venezuela's AG asks Interpol to issue arrest warrant for Argentina's Milei
Israel open to ideas to de-escalate in Lebanon, says Israel's UN envoy
US highway program's use of race, gender in contracting is unlawful, judge says
Bowman, Briscoe and Cindric step up in postseason to advance in NASCAR playoffs
Phillies know 1st NL East title since 2011 only small step toward World Series championship
Elon Musk, X seek dismissal of Don Lemon's lawsuit over canceled partnership
By Mariam Sunny and Manas Mishra
(Reuters) -The U.S. Food and Drug Administration on Thursday approved updated COVID-19 vaccines made by Pfizer and Moderna targeting a recent variant of the disease, in time for a fall vaccination campaign.
The updated shots target the KP.2 variant that was circulating earlier this year. They are expected to be available across the country in the coming days, the companies said.
The health regulator had asked vaccine manufacturers in June to target the variant, if feasible.
The latest vaccines are designed to more closely target currently circulating variants and better protect against the disease's severe symptoms. The older shots targeted a variant that is no longer circulating.
"Vaccination continues to be the cornerstone of COVID-19 prevention," said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research.
KP.2 is no longer dominant but is still related to other variants currently circulating in the United States. Health regulators hope to protect against circulating variants by targeting closely related forms such as KP.2.
The FDA cleared the use of Moderna's shot, branded as Spikevax, and Comirnaty, which is jointly developed by Pfizer and BioNTech, in both children aged six months and older, and adults.
The shots for children below 12 years are cleared under the agency's emergency use authorization pathway.
The regulator did not approve a more traditional protein-based shot made by Novavax, which can offer an alternative to people skeptical of the mRNA vaccines made by Moderna and Pfizer.
Novavax said it was working "productively" with the FDA and expects to have authorization in time for peak vaccination season.
The company's vaccine is developed in moth cells and takes months to manufacture. In 2023, for instance, Novavax said it needed six months to bring an adequate supply of the vaccine to the market.
The approvals come at a time when COVID-19-related hospitalizations and deaths have increased over the past three months in the United States. Demand for the shots, however, has fallen sharply since the peak of the pandemic.
(Reporting by Manas Mishra and Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
